COMBINATION OF MCL-1 INHIBITOR AND MIDOSTAURIN, ITS APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS Russian patent published in 2024 - IPC A61K31/519 A61K31/553 A61K31/704 A61K31/706 A61P35/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to the treatment of a malignant neoplasm. Combination for treating acute myeloid leukemia comprises midostaurin or a pharmaceutically acceptable salt thereof, or a complex thereof, or a co-crystal thereof, or a solvate thereof, including a hydrate, and an Mcl-1 inhibitor, which is Compound B: (2R)-2-{[(5Sa)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propane acid, or Compound C: (2R)-2-{[(5Sa)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(5-fluorofuran)-2-yl)thieno[2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]methoxy}phenyl)propanoic acid, or their enantiomers, diastereomers, atropisomers, or their addition salts with a pharmaceutically acceptable acid or base, in an effective amount for simultaneous, sequential or separate application. Also disclosed is a pharmaceutical composition for treating acute myeloid leukemia, use of the combination for preparing a drug for treating acute myeloid leukemia.

EFFECT: group of inventions provides a synergetic interaction by inhibiting cell proliferation.

19 cl, 18 dwg, 3 ex